Trial · NCT01263509
Results by group124
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 124
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | Serious Adverse Event | 6 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | Serious Adverse Event | 7 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | Serious Adverse Event Related to Study Drug | 0 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | Serious Adverse Event Related to Study Drug | 1 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | Other Adverse Events (Incidence ≥3%) | 85 | participants | |
| Number of Participants With Adverse Events. | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | Other Adverse Events (Incidence ≥3%) | 73 | participants | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.69 | Standard Deviation 0.479 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 8). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.79 | Standard Deviation 0.417 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.89 | Standard Deviation 0.589 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 12). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 | Standard Deviation 0.486 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 16). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.91 | Standard Deviation 0.658 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 16). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 | Standard Deviation 0.587 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 20). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.90 | Standard Deviation 0.745 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 20). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 | Standard Deviation 0.592 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 24). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.83 | Standard Deviation 0.750 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 24). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.88 | Standard Deviation 0.624 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 28). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 | Standard Deviation 0.704 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 28). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 | Standard Deviation 0.619 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 32). | Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.80 | Standard Deviation 0.701 | percentage of Glycosylated Hemoglobin | |
| Change From Baseline in Glycosylated Hemoglobin (Week 32). | Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.85 | Standard Deviation 0.679 | percentage of Glycosylated Hemoglobin |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263509/results